This category page covers biotechnology and pharmaceutical companies developing therapies that target the cGAS-STING (cyclic GMP-AMP synthase - Stimulator of Interferon Genes) pathway for the treatment of neurodegenerative diseases, particularly Parkinson's disease and Alzheimer's disease.
The cGAS-STING pathway is a cytosolic DNA sensing mechanism that triggers type I interferon responses. In neurodegenerative diseases, activation of this pathway contributes to neuroinflammation and neuronal death through multiple mechanisms:
| Company | Drug | Mechanism | Stage | Indication |
|---|---|---|---|---|
| Denali Therapeutics | DNL787 | STING antagonist | Preclinical | PD, AD |
| Nodthera | NT-0896 | cGAS/STING dual inhibitor | Preclinical | Neurodegeneration |
| Vedanta Biosciences | VE707 | STING modulator | Research | PD, AD |
Denali has a strong foundation in lysosomal biology and has been expanding into innate immune pathways. Their STING program builds on expertise in neuroinflammation and microglial biology.
Nodthera, known for their NLRP3 inhibitor NT-0796 in Phase 1/2 for AD, is developing next-generation compounds that target both NLRP3 and cGAS-STING pathways given their synergistic roles in neuroinflammation.
Vedanta Biosciences is known for their expertise in immune modulation and live biotherapeutic products. Their STING program represents an expansion into neurodegenerative disease.
The following compounds are widely used in research but have not yet reached clinical development for neurodegeneration:
| Compound | Mechanism | Developer/Source | Notes |
|---|---|---|---|
| H-151 | Covalent STING inhibitor | Research compound | Prevents STING palmitoylation |
| C-176 | STING antagonist | Research compound | Blocks STING trafficking |
| C-178 | STING inhibitor | Research compound | Neuroprotection in models |
| GYS1460 | STING antagonist | Research | Reduces neuroinflammation in PD models |
| RU.521 | cGAS antagonist | Research compound | Selective for cGAS |
| Target | Approach | Companies | Stage |
|---|---|---|---|
| cGAS | Direct inhibition | Nodthera | Preclinical |
| STING | Antagonist | Denali | Preclinical |
| TBK1 | Kinase inhibition | Research | Research |
| Type I IFN | Receptor blockade | Research | Research |
The cGAS-STING field for neurodegeneration is emerging, with companies positioning themselves:
| Company | Primary Focus | STING Program Status |
|---|---|---|
| Denali Therapeutics | CNS delivery | Preclinical |
| Nodthera | Dual inflammasome/STING | Preclinical |
| Vedanta Biosciences | Immune modulation | Research |
| Mechanism | Key Companies | Stage | Notable |
|---|---|---|---|
| NLRP3 Inflammasome | Nodthera, Olatec | Phase 1-2 | NT-0796 |
| TREM2 | Alector, Denali | Phase 1-2 | AL002 |
| TNF-α | INmune Bio | Phase 2 | XPro1595 |
| cGAS-STING | Denali, Nodthera | Preclinical | DNL787 |
Currently, no cGAS-STING inhibitors have reached clinical trials for neurodegenerative diseases. The field is in preclinical development with several programs expected to enter Phase 1 within the next 2-3 years.
Many STING antagonists have limited CNS penetration. Companies are developing brain-penetrant formulations:
The cGAS-STING pathway represents an emerging target in neuroinflammation with several advantages:
Challenges include: